Intranasal Vaccine Serum Institute’s solution to Covid-19 New Delhi, India, 19th October

Serum Institute to begin manufacturing Intranasal Vaccine for Covid 19 Ministry of India informed

On Sunday morning, our health minister Harsh Vardhan enlightened us with the current progress in the field of Covid vaccine. He said that in the running in India three vaccines are being tested on the citizens, currently shutting the rumors he said intranasal testing is not yet started on citizens in India. However, he confirmed that Serum Institute was actually manufacturing intranasal vaccine candidates.

 Following which he also said, “Flumist nasal spray is a vaccine that is sprayed into the nose to help protest against influenza; it is not a Covid-19 vaccine. At present in India, there is no intranasal Covid vaccine which is under clinical trials. However, Serum Institute (of India) has begun manufacturing Codagenix CDX 005, which is an intranasal live attenuated vaccine candidate for Sars-Cov-2,”

After the detailed information people on social media started posting queries related to the ministers saying and he wholeheartedly further clearing ever doubts of citizens went in social media and posted, “Pre clinical animal studies have already been completed and Codagenix expects to initiate a phase 1 clinical first in humans trial in the United Kingdom by the end of 2020.Further, Serum India plans to undertake clinical developments of this vaccine candidate in India.” The minister was doing so because of the sixth episode of the Sunday samvad.

In the episode, it was revealed that Bharat Biotech has keenly signed an agreement with Washington University School of Medicine. The corundum Indian organization has signed up for marketing along with testing trials for intranasal vaccine against the coronavirus.

To one of the queries, “The phase 1 trials will take place in the US in St. Louis University’s vaccine and treatment evaluation unit, on getting regulatory approval, Bharat Biotech will pursue further stages of clinical trials in India,”  

A candidate questioned which age group is being tested generally so further informing the processor he added that 1st clinical trial is subjected to 55 years to 18 years for Phase 1 and things go along and successfully in Phase 2 the subjects were also 12 year old to 65 years. These procedures are followed by Bharat Biotech.  

Some named pharmaceuticals include the age group 18-55; for example, Cadila Healthcare’s 18-55 years are the subject for the first trial procedure only. Serum Institute on the other hand has included 18 ears and onwards approx. 99 in the 2nd and 3rd phase vaccine trial.

As analysing, it is hard to come to any conclusion that which vaccine would work, as the number of people enrolled for the trial are very less in both the phases. After getting the result of the third trial that is bound to take place in a large number we could gather a concrete conclusion.

“Phase 1/2 trials show promise, while phase 3 is about knowing the performance,” said Dr K Srinath Reddy, founder, Public Health Foundation of India.